Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Artur Jurczyszyn; Jorge J. Castillo; Irit Avivi; Jacek Czepiel; Julio Davila; Ravi Vij; Mark A. Fiala; Alessandro Gozzetti; Norbert Grząśko; Vibor Milunovic; Iwona Hus; Krzysztof Mądry; Anna Waszczuk-Gajda; Lidia Usnarska-Zubkiewicz; Jakub Dębski; Erden Atilla; Meral Beksac; Giuseppe Mele; Waldemar Sawicki; David Jayabalan; Grzegorz Charliński; Agoston Gyula Szabo; Roman Hajek; Michel Delforge; Agnieszka Kopacz; Dorotea Fantl; Anders Waage; Edvan Crusoe; Vania Hungria; Paul Richardson; Jacob Laubach; Thomas Guerrero-Garcia; Jieqi Liu; David H. Vesole

doi:10.1080/10428194.2018.1473574

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Artur Jurczyszyn, Jorge J. Castillo, Irit Avivi, Jacek Czepiel, Julio Davila, Ravi Vij, Mark A. Fiala, Alessandro Gozzetti, Norbert Grząśko, Vibor Milunovic, Iwona Hus, Krzysztof Mądry, Anna Waszczuk-Gajda, Lidia Usnarska-Zubkiewicz, Jakub Dębski, Erden Atilla, Meral Beksac, Giuseppe Mele, Waldemar Sawicki, David JayabalanGrzegorz Charliński, Agoston Gyula Szabo, Roman Hajek, Michel Delforge, Agnieszka Kopacz, Dorotea Fantl, Anders Waage, Edvan Crusoe, Vania Hungria, Paul Richardson, Jacob Laubach, Thomas Guerrero-Garcia, Jieqi Liu, David H. Vesole

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 10 ⁹ /L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p =.0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.

Original language	English
Pages (from-to)	118-123
Number of pages	6
Journal	Leukemia and Lymphoma
Volume	60
Issue number	1
DOIs	https://doi.org/10.1080/10428194.2018.1473574
State	Published - Jan 2 2019

Keywords

Autologous stem cell transplantation
proteasome inhibitors
secondary plasma cell leukemia

Access to Document

10.1080/10428194.2018.1473574

Cite this

Jurczyszyn, A., Castillo, J. J., Avivi, I., Czepiel, J., Davila, J., Vij, R., Fiala, M. A., Gozzetti, A., Grząśko, N., Milunovic, V., Hus, I., Mądry, K., Waszczuk-Gajda, A., Usnarska-Zubkiewicz, L., Dębski, J., Atilla, E., Beksac, M., Mele, G., Sawicki, W., ... Vesole, D. H. (2019). Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 60(1), 118-123. https://doi.org/10.1080/10428194.2018.1473574

@article{1dd4c7e29e8144c990a9648b27455091,

title = "Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients",

abstract = " This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 10 9 /L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p =.0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.",

keywords = "Autologous stem cell transplantation, proteasome inhibitors, secondary plasma cell leukemia",

author = "Artur Jurczyszyn and Castillo, {Jorge J.} and Irit Avivi and Jacek Czepiel and Julio Davila and Ravi Vij and Fiala, {Mark A.} and Alessandro Gozzetti and Norbert Grz{\c a}{\'s}ko and Vibor Milunovic and Iwona Hus and Krzysztof M{\c a}dry and Anna Waszczuk-Gajda and Lidia Usnarska-Zubkiewicz and Jakub D{\c e}bski and Erden Atilla and Meral Beksac and Giuseppe Mele and Waldemar Sawicki and David Jayabalan and Grzegorz Charli{\'n}ski and {Gyula Szabo}, Agoston and Roman Hajek and Michel Delforge and Agnieszka Kopacz and Dorotea Fantl and Anders Waage and Edvan Crusoe and Vania Hungria and Paul Richardson and Jacob Laubach and Thomas Guerrero-Garcia and Jieqi Liu and Vesole, {David H.}",

note = "Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = jan,

day = "2",

doi = "10.1080/10428194.2018.1473574",

language = "English",

volume = "60",

pages = "118--123",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "1",

}

Jurczyszyn, A, Castillo, JJ, Avivi, I, Czepiel, J, Davila, J, Vij, R , Fiala, MA, Gozzetti, A, Grząśko, N, Milunovic, V, Hus, I, Mądry, K, Waszczuk-Gajda, A, Usnarska-Zubkiewicz, L, Dębski, J, Atilla, E, Beksac, M, Mele, G, Sawicki, W, Jayabalan, D, Charliński, G, Gyula Szabo, A, Hajek, R, Delforge, M, Kopacz, A, Fantl, D, Waage, A, Crusoe, E, Hungria, V, Richardson, P, Laubach, J, Guerrero-Garcia, T, Liu, J & Vesole, DH 2019, 'Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients', Leukemia and Lymphoma, vol. 60, no. 1, pp. 118-123. https://doi.org/10.1080/10428194.2018.1473574

TY - JOUR

T1 - Secondary plasma cell leukemia

T2 - a multicenter retrospective study of 101 patients

AU - Jurczyszyn, Artur

AU - Castillo, Jorge J.

AU - Avivi, Irit

AU - Czepiel, Jacek

AU - Davila, Julio

AU - Vij, Ravi

AU - Fiala, Mark A.

AU - Gozzetti, Alessandro

AU - Grząśko, Norbert

AU - Milunovic, Vibor

AU - Hus, Iwona

AU - Mądry, Krzysztof

AU - Waszczuk-Gajda, Anna

AU - Usnarska-Zubkiewicz, Lidia

AU - Dębski, Jakub

AU - Atilla, Erden

AU - Beksac, Meral

AU - Mele, Giuseppe

AU - Sawicki, Waldemar

AU - Jayabalan, David

AU - Charliński, Grzegorz

AU - Gyula Szabo, Agoston

AU - Hajek, Roman

AU - Delforge, Michel

AU - Kopacz, Agnieszka

AU - Fantl, Dorotea

AU - Waage, Anders

AU - Crusoe, Edvan

AU - Hungria, Vania

AU - Richardson, Paul

AU - Laubach, Jacob

AU - Guerrero-Garcia, Thomas

AU - Liu, Jieqi

AU - Vesole, David H.

PY - 2019/1/2

Y1 - 2019/1/2

N2 - This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 10 9 /L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p =.0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.

AB - This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 10 9 /L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p =.0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.

KW - Autologous stem cell transplantation

KW - proteasome inhibitors

KW - secondary plasma cell leukemia

UR - http://www.scopus.com/inward/record.url?scp=85049602239&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1473574

DO - 10.1080/10428194.2018.1473574

M3 - Article

C2 - 29965787

AN - SCOPUS:85049602239

SN - 1042-8194

VL - 60

SP - 118

EP - 123

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this